Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications.
Krzysztof Piotr MichalakAleksandra Sobolewska-WłodarczykMarcin WłodarczykJustyna SobolewskaPiotr WoźniakBogusław SobolewskiPublished in: Oxidative medicine and cellular longevity (2017)
Long-term fluoroquinolone-associated disability (FQAD) after fluoroquinolone (FQ) antibiotic therapy appears in recent years as a significant medical and social problem, because patients suffer for many years after prescribed antimicrobial FQ treatment from tiredness, concentration problems, neuropathies, tendinopathies, and other symptoms. The knowledge about the molecular activity of FQs in the cells remains unclear in many details. The effective treatment of this chronic state remains difficult and not effective. The current paper reviews the pathobiochemical properties of FQs, hints the directions for further research, and reviews the research concerning the proposed treatment of patients. Based on the analysis of literature, the main directions of possible effective treatment of FQAD are proposed: (a) reduction of the oxidative stress, (b) restoring reduced mitochondrion potential ΔΨm,
Keyphrases
- oxidative stress
- healthcare
- multiple sclerosis
- mental health
- systematic review
- end stage renal disease
- stem cells
- randomized controlled trial
- induced apoptosis
- chronic kidney disease
- staphylococcus aureus
- newly diagnosed
- cell death
- physical activity
- bone marrow
- replacement therapy
- signaling pathway
- prognostic factors
- pi k akt
- ejection fraction
- single molecule
- drug induced
- patient reported